Federal health officials have proposed a revamp of patient confidentiality regulations to encourage coordination among medical professionals treating people for opioid addiction.
A fivefold increase was seen in Medicaid-covered prescriptions for buprenorphine during 2011 to 2018.
Individuals taking extended-release injection naltrexone for opioid use disorder may be less likely to drop out of treatment after a single use of opioids compared with patients receiving placebo.
Regional variation in naloxone dispensing considerable; rates lowest in most rural counties.
Prenatal opioid exposure may be associated with poorer cognitive and motor development in children from age 6 months to adolescence.
An estimated 20 million people in the United States meet the criteria for substance use disorder.
A panel of experts addressed several challenges associated with the implementation of the 2016 Centers for Disease Control and Prevention Guideline for Prescribing Opioids for Chronic Pain.
The demand for naloxone is relatively inelastic with respect to changes in its out-of-pocket price, and conversion to an over-the-counter medication is expected to increase naloxone pharmacy sales.
A relationship between opioid withdrawal, pain catastrophizing, and the experience of pain may be present in women with chronic pain who misuse prescription opioids.
Drug manufacturers and distributors will now be able to access a Drug Enforcement Administration (DEA) database that monitors controlled substances from the point of manufacture all the way through to the point of sale.